The Best of SABCS 2023 will present a summary of the most significant treatment advances presented at the annual San Antonio Breast Cancer Symposium®. Presentations will be given by key opinion leaders across Canada and will focus on the latest research with in-depth analysis and discussion to improve the current standard of cancer care.
- Describe key clinical trial data from 2022 in the management of breast cancer and understand the impact on Canadian practices.
- Understand the latest strategies in breast cancer pathology, radiation, and surgery
- Implement approaches that maximize patient standard of care in breast cancer
In Person & Free Virtual Registration Options Below:
For the safety of our registrants and the vulnerable patient population they serve, we strongly encourage the use of masks by all attendees. This is also a reminder that all attendees must be fully vaccinated against COVID-19 by the time of the event.
EARLY BIRD PRICING ENDS JANUARY 12th
Registration for Healthcare professionals can be completed above. Industry representatives (both sponsor and non-sponsor) must contact Kelly Allan at email@example.com for registration and sponsorship opportunities.
Join Us Live In Person at the
BMO IFL in Toronto
Times listed are EST
- Timezone: America/New_York
- Date: Friday, February 10, 2023
- Time: 8:00 am - 4:00 pm
8:00 am – 9:00 am
Registration and Breakfast Buffet
9:00 am – 9:15 am
Welcome Address by Chairs – Dr. Christine Brezden-Masley and Dr. David Cescon
9:15 am – 10:00 am
Gilead Breakfast Symposium – TBA
10:00 am – 10:30 am
Early HER2 Positive Breast Cancer – Dr. Ana Lohman
10:30 am – 11:00 am
Metastatic HER2 Positive Breast Cancer – Dr. Arif Awan
11:00 am – 11:20 am
Networking Break & Sponsor Exhibits
11:20 am – 11:30 am
Surgical Updates – TBA
11:30 am – 11:40 am
Radiation Updates – TBA
11:40 am – 11:55 am
Pathology (Biomarkers) Updates – TBA
11:55 am – 12:10 pm
Q & A and Discussion with Panel
12:10 pm – 12:40 pm
Lunch Buffet & Break
12:40 pm – 1:25 pm
Eli Lilly Lunch Symposium: The evolving role of the cdk 4/6 inhibitors in early high risk and metastatic breast cancers – Dr. Stephen Chia
1:25 pm – 1:55 pm
Neoadjuvant / Adjuvant Triple Negative Breast Cancer – Dr. Erin Powell
1:55 pm – 2:25 pm
Metastatic Triple Negative Breast Cancer – TBA
2:25 pm – 2:45 pm
Networking Break & Sponsor Exhibits
2:45 pm – 3:10 pm
Early ER Positive Breast Cancer (Neoadjuvant) – Dr. Nancy Nixon
3:10 pm – 3:35 pm
Metastatic ER Positive – Dr. Brooke Wilson
3:35 pm – 4:05 pm
Novel Therapeutics in Breast Cancer – What’s in the Pipeline Development? – Dr. Jesus Fuentes
4:05 pm – 4:15 pm
Closing Remarks by Chairs – Dr. Christine Brezden-Masley & Dr. David Cescon
About the Faculty
Dr. Christine Brezden-Masley
Christine Brezden-Masley, MD PhD FRCPC is a practicing Medical Oncologist and the Director of the Marvelle Koffler Breast Centre at Mount Sinai Hospital as well as the Medical Director of Cancer Program for Sinai Health in Toronto, Canada. She obtained her PhD in Medical Biophysics at the Princess Margaret Hospital in Toronto and her Medical Degree from the University of Toronto. She is currently an Associate Professor at the University of Toronto and senior scientist for the same Clinical Research Group at the Lunenfeld-Tanenbaum Research Institute for Sinai Health System in Toronto, Canada.
Dr. Brezden-Masley is the founder of the COMET (Community Oncologists of Metropolitan Toronto) Clinical Trials Consortium, a web-based virtual network promoting cancer clinical trials throughout the Toronto region. She treats both breast and gastrointestinal(colorectal and gastric cancers) malignancies, which are her major areas of research interest. Her main area of clinical research is cardiotoxicity from cancer therapy and is currently the President of the Canadian Cardio-Oncology Network. She is also on the Board of Directors of ReThink Breast Cancer, a national advocacy and support network for young women with breast cancer and My Gut Feeling, a stomach cancer support network for patients, survivors, and caregivers.
Dr. David Cescon
Dr. David Cescon is a breast medical oncologist and clinician scientist at Princess Margaret Cancer Centre in Toronto. His clinical and academic interests include drug and biomarker development, and the application of circulating tumour DNA technologies in breast cancer. He is a member of multiple international breast cancer clinical trial initiatives and is the incoming chair of the Canadian Cancer Trials Group IND program.